Tomasz Pawlowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2791051/publications.pdf

Version: 2024-02-01

840728 642715 36 548 11 23 citations h-index g-index papers 40 40 40 766 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Feasibility and safety of the new coronary noncompliant balloon catheter River NC®. Future Cardiology, 2021, 17, 1123-1130.	1.2	1
2	Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent. Medicine (United States), 2019, 98, e15106.	1.0	2
3	An optical coherence tomography study of neointimal morphology and strut coverage at different time intervals from implantation of biodegradable polymerâ€coated sirolimusâ€eluting stents. Catheterization and Cardiovascular Interventions, 2018, 92, 302-309.	1.7	5
4	Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up. International Journal of Cardiovascular Imaging, 2018, 34, 353-365.	1.5	11
5	A comparison of intracoronary treatment strategies for thrombus burden removal during primary percutaneous coronary intervention. Coronary Artery Disease, 2018, 29, 186-193.	0.7	2
6	Secular trends in first-time hospitalization for heart failure with following one-year readmission and mortality rates in the 3.8 million adult population of Silesia, Poland between 2010 and 2016. The SILCARD database. International Journal of Cardiology, 2018, 271, 146-151.	1.7	10
7	Advances in Mechanisms and Treatment Options of MINOCA Caused by Vasospasm or Microcirculation Dysfunction. Current Pharmaceutical Design, 2018, 24, 517-531.	1.9	9
8	First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C® — three-month results. Kardiologia Polska, 2018, 76, 464-470.	0.6	8
9	Rotational atherectomy in everyday clinical practice. Association of Cardiovascular Interventions of the Polish Society of Cardiology (Asocjacja Interwencji Sercowo-Naczyniowych Polskiego) Tj ETQq1 1 0.784314	4 rg BoT. ∳Ove	erlo ck 10 Tf 50
10	Assessment of vascular response to Bi <scp>OSS LIM</scp> C [®] stents vs Orsiro [®] stents in the porcine coronary artery model. Cardiovascular Therapeutics, 2017, 35, e12267.	2.5	6
11	The role of residual intrastent thrombus during primary angioplasty. Journal of Cardiovascular Medicine, 2017, 18, 348-353.	1.5	2
12	Effects of Transendocardial Delivery of Bone Marrow–Derived CD133 ⁺ Cells on Left Ventricle Perfusion and Function in Patients With Refractory Angina. Circulation Research, 2017, 120, 670-680.	4.5	35
13	Second-generation drug-eluting stents in the elderly patients with acute coronary syndrome: the in-hospital and 12-month follow-up of the all-comer registry. Aging Clinical and Experimental Research, 2017, 29, 885-893.	2.9	1
14	Gender differences and bleeding complications after PCI on first and second generation DES. Scandinavian Cardiovascular Journal, 2017, 51, 53-60.	1.2	6
15	Long-Term Percutaneous Coronary Intervention Outcomes of Patients with Chronic Kidney Disease in the Era of Second-Generation Drug-Eluting Stents. CardioRenal Medicine, 2017, 7, 85-95.	1.9	9
16	Self-positioning properties of dedicated bifurcation coronary stent BiOSS LIM® in the eye of 3D optical coherence tomography. Minerva Cardiology and Angiology, 2017, 65, 194-196.	0.7	3
17	Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction. Journal of Cardiovascular Medicine, 2016, 17, 701-706.	1.5	4
18	Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM® dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry. EuroIntervention, 2016, 12, 1246-1254.	3.2	12

#	Article	IF	Citations
19	Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM® stent: the randomised, multicentre, open-label, controlled POLBOS II trial. EuroIntervention, 2016, 12, e1404-e1412.	3.2	27
20	Impact of anaemia on long-term outcomes in patients treated with first- and second-generation drug-eluting stents; Katowice-Zabrze Registry. Kardiologia Polska, 2016, 74, 561-569.	0.6	5
21	The use of bioresorbable vascular scaffold Absorb BVS \hat{A}^{\odot} in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment. Kardiologia Polska, 2016, 74, 627-633.	0.6	9
22	Novel sirolimus-eluting stent Prolim $\hat{A}^{@}$ with a biodegradable polymer in the all-comers population: one year clinical results with quantitative coronary angiography and optical coherence tomography analysis. BMC Cardiovascular Disorders, 2015, 15, 150.	1.7	8
23	Coronary spasm revascularized with a bioresorbable vascular scaffold. Coronary Artery Disease, 2015, 26, 634-636.	0.7	5
24	Percutaneous interventions in cardiology in Poland in the year 2014. Summary report of the Association of Cardiovascular Interventions of the Polish Cardiac Society AISN PTK. Postepy W Kardiologii Interwencyjnej, 2015, 3, 177-181.	0.2	11
25	Randomized evaluation of intralesion versus intracoronary abciximab and aspiration thrombectomy in patients with ST-elevation myocardial infarction: The COCTAIL II trial. American Heart Journal, 2015, 170, 1116-1123.	2.7	27
26	Dedicated Bifurcation Paclitaxelâ€Eluting Stent BiOSS Expert® in the Treatment of Distal Left Main Stem Stenosis. Journal of Interventional Cardiology, 2014, 27, 242-251.	1.2	26
27	Statistics regarding interventional cardiology in Poland in 2013. Summary report of the Association of Cardiovascular Interventions of the Polish Cardiac Society (AISN PTK). Kardiologia Polska, 2014, 72, 1402-1407.	0.6	1
28	Optical coherence tomography criteria for defining functional severity of intermediate lesions: a comparative study with FFR. International Journal of Cardiovascular Imaging, 2013, 29, 1685-1691.	1.5	38
29	Randomized trial of standard versus ClearWay-infused abciximab and thrombectomy in myocardial infarction. Journal of Cardiovascular Medicine, 2013, 14, 364-371.	1.5	12
30	Transradial Approach to All Interventional Procedures. JACC: Cardiovascular Interventions, 2010, 3, 463.	2.9	5
31	Local Delivery Versus Intracoronary Infusion of Abciximab in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2010, 3, 928-934.	2.9	73
32	Intravascular ultrasound guidance may be an option for coronary interventions. Catheterization and Cardiovascular Interventions, 2008, 72, 750-751.	1.7	0
33	Transient left apical ballooning syndromeâ€"The need for common terminology?. International Journal of Cardiology, 2008, 131, 138-139.	1.7	3
34	Comparison of angiographically guided direct stenting technique with direct stenting and optimal balloon angioplasty guided with intravascular ultrasound. The multicenter, randomized trial results. American Heart Journal, 2007, 154, 669-675.	2.7	41
35	Stenting of Culprit Lesions in Unstable Angina Leads to a Marked Reduction in Plaque Burden: A Major Role of Plaque Embolization?. Circulation, 2003, 107, 2320-2325.	1.6	95
36	Intravascular ultrasound and quantitative coronary angiography assessment of late in-stent restenosis: In vivo human correlation and methodological implications. Catheterization and Cardiovascular Interventions, 2002, 57, 155-160.	1.7	19